Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company’s ...
Wave Life Sciences Ltd WVE announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results